PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer. Clin. Transl. Oncol. 23, 1827–1837 (2021). Article CAS PubMed Google Scholar Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G. & Galluzzi, L. ...
A variety of targeted anticancer agents have been successfully introduced into clinical practice, largely reflecting their ability to inhibit specific molecular alterations that are required for disease progression. However, not all malignant cells rely on such alterations to survive, proliferate, disseminate...